WallStSmart

Baird Medical Investment Holdings Limited (BDMD)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 91367% more annual revenue ($20.61B vs $22.54M). BSX leads profitability with a 17.3% profit margin vs -121.0%. BSX earns a higher WallStSmart Score of 76/100 (B+).

BDMD

Avoid

24

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 1/9Altman Z: -0.02

BSX

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 6.3
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BDMD.

BSXSignificantly Overvalued (-29.4%)

Margin of Safety

-29.4%

Fair Value

$37.35

Current Price

$48.55

$11.20 premium

UndervaluedFair: $37.35Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDMD1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$70.87B9/10

Large-cap with strong market position

PEG RatioValuation
0.588/10

Growing faster than its price suggests

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

Areas to Watch

BDMD4 concerns · Avg: 2.5/10
Market CapQuality
$42.86M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-48.1%2/10

ROE of -48.1% — below average capital efficiency

Revenue GrowthGrowth
-39.0%2/10

Revenue declined 39.0%

BSX0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : BDMD

The strongest argument for BDMD centers on Price/Book.

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bear Case : BDMD

The primary concerns for BDMD are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Key Dynamics to Monitor

BDMD profiles as a turnaround stock while BSX is a mature play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.62 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (76/100 vs 24/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Baird Medical Investment Holdings Limited

HEALTHCARE · MEDICAL DEVICES · USA

Baird Medical Investment Holdings Limited, along with its subsidiaries manufactures microwave ablation and other medical devices for minimally invasive tumor treatment. The company is headquartered in Guangzhou, China.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?